Tamoxifen and Clomiphene Citrate in Mild Stimulation IVF

Comparison of Tamoxifen and Clomiphene Citrate in Mild Stimulation IVF: a Prospective Cohort Study

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02690870

Enrollment

210

Registered

2016-02-24

Start date

2017-01-31

Completion date

2019-03-31

Last updated

2016-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Keywords

tamoxifen, clomiphene, mild stimulation, poor ovarian response, clinical pregnancy rate

Brief summary

The purpose of this prospective cohort study is to compare IVF outcome between tamoxifen and clomiphene citrate in mild stimulation.

Detailed description

The reported prevalence of poor ovarian responders amongst patients undergoing IVF-ET is 9%-24%, and morbidity must be higher nowadays. For these women, Mild stimulation has been an important ovulation induction protocol. Clomiphene citrate(CC) and tamoxifen(TMX) are commonly used in mild stimulation protocol. It's reported that CC has adverse effect on growth of endrometrium and results in thin endrometrium(≤7mm) which maybe affect pregnancy rate. However, TMX has estrogen-like effect on the endrometrium that may be helpful to increase endormetrial thickness. The reported results about comparing CC with TMX showed that they had similar ovulation rate. Prospective study is necessary to confirm whether TMX is superior to CC on the IVF outcome.

Interventions

DRUGTamoxifen

Patients in the tamoxifen group will take 20 mg of tamoxifen oral tablets daily from day 3 of the menses for 5 days.

DRUGClomiphene

Patients in clomiphene group will take 100 mg of CC oral tablets daily from day 3 of the menses for 5 days.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

37 Years to 42 Years

Healthy volunteers

Inclusion criteria

1. age between 37 and 42; 2. BMI≤23kg/m2; 3. ≤3 oocytes with a conventional stimulation protocol; 4. AFC\<5 follicles or AMH\<1.1 ng/ml on the day 1 to 5 of the menses; 5. Cause of Infertiity: tubal factor, male factor, diminished ovarian reserve.

Exclusion criteria

1. endormetrial polyp, endormetrial cancer,intrauterine adhesions,uterine fibroids that affects uterine cavity 2. Endometriosis, adenomyosis 3. The diameter of Hydrosalpinx \>2cm

Design outcomes

Primary

Measure	Time frame
clinical pregnancy rate	four weeks after embryo transfer

Secondary

Measure	Time frame
cycle cancellations for thin endrometrial thickness	on the HCG day
endrometrial pattern and thickness on the day of HCG administration	on the HCG day
the number of follicular diameter≥10mm and sexual hormone test on the HCG day	on the HCG day

Contacts

Primary ContactHaiyan LIN

linhaiyan_818@163.com0018615913154456

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026